• 24 August, 2025

Boehringer loses India patent to Cipla

March 16, 2015 | Monday | News | By BioSpectrum Bureau

Boehringer loses India patent to Cipla

(Photo Courtesy: www.thekansascitylawyer.com)

(Photo Courtesy: www.thekansascitylawyer.com)

In a landmark decision, India's patent office has revoked the patent of German-based pharmaceutical giant Boehringer Ingelheim's chronic obstructive pulmonary disease drug Spiriva (tiotropium).

Back in 2012, Boehringer received its Indian patent on Spiriva, which extended up to 2021.

In 2013, Cipla filed its patent opposition saying the drug didn't constitute invention under India's patent laws.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Can Policy Reforms & Investments Trigger India’s MedTech Makeover?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy